← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry-results
Intratympanic sodium thiosulfate otoprotection pilot study
Also known as: Sodium Thiosulfate, STS, sodium thiosulphate, 11D.99, JT 2092, NCT01369641
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Drug Delivery
Stage
Interventional/NA
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic drops
Confidence
82%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
United States
Population
adult, cisplatin-ototoxicity, otoprotection, terminated-study
Trial IDs
1
Mechanism
Local intratympanic sodium thiosulfate drops evaluated as otoprotection against cisplatin-associated hearing loss.
Indications
Notes
Split from a mixed generated sodium-thiosulfate record. This Thomas Jefferson intratympanic STS pilot was terminated for poor accrual and posted limited results; it should not be merged with TRPHARM/Fennec pediatric expanded access.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, programType, modality, stage, status...
IDs: NCT01369641, 11D.99, JT 2092
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyterminated-studyresults-postedsplit-from-mixed-sodium-thiosulfate-record
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2